Search research articles
Contact Us
Filters
Showing results (441-450 of 468) with videos related to
Page
of 47
Sort By:
Neurology. Genetics
|
June 24, 2022
Genome Sequencing in the Parkinson Disease Clinic
Emily J Hill, Laurie A Robak, Rami Al-Ouran, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi
|
January 24, 2019
Sudden arrhythmia death syndrome in young victims: a five-year retrospective review and two-year prospective molecular autopsy study by next-generation sequencing and clinical evaluation of their first-degree relatives
C M Mak, N S Mok, H C Shum, et al.
Gynecologic Oncology
|
October 23, 2022
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma
David M O'Malley, Amit M Oza, Domenica Lorusso, et al.
Brain : a Journal of Neurology
|
October 3, 2014
Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion
Suzee E Lee, Anna M Khazenzon, Andrew J Trujillo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 9, 2021
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
Andrew R Clamp, Domenica Lorusso, Amit M Oza, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 9, 2012
Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion
Baber K Khan, Jennifer S Yokoyama, Leonel T Takada, et al.
The Lancet. Oncology
|
May 4, 2020
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
Jonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Cancer Medicine
|
September 22, 2021
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety
Ana Oaknin, Amit M Oza, Domenica Lorusso, et al.
Gynecologic Oncology
|
August 31, 2020
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma
Nicoletta Colombo, Amit M Oza, Domenica Lorusso, et al.
Geohealth
|
April 3, 2026
Developing Scenario-Based Strategies for Health, Climate, and Environmental Preparedness: The One Health, One Earth Approach
Azar M Abadi, Kyle D Brumfield, Moiz Usmani, et al.
Page
of 47
Search research articles
Search
Showing results (441-450 of 468) with videos related to
Sort By:
Page
of 47
Neurology. Genetics
|
June 24, 2022
Genome Sequencing in the Parkinson Disease Clinic
Emily J Hill, Laurie A Robak, Rami Al-Ouran, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi
|
January 24, 2019
Sudden arrhythmia death syndrome in young victims: a five-year retrospective review and two-year prospective molecular autopsy study by next-generation sequencing and clinical evaluation of their first-degree relatives
C M Mak, N S Mok, H C Shum, et al.
Gynecologic Oncology
|
October 23, 2022
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma
David M O'Malley, Amit M Oza, Domenica Lorusso, et al.
Brain : a Journal of Neurology
|
October 3, 2014
Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion
Suzee E Lee, Anna M Khazenzon, Andrew J Trujillo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 9, 2021
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
Andrew R Clamp, Domenica Lorusso, Amit M Oza, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 9, 2012
Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion
Baber K Khan, Jennifer S Yokoyama, Leonel T Takada, et al.
The Lancet. Oncology
|
May 4, 2020
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
Jonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Cancer Medicine
|
September 22, 2021
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety
Ana Oaknin, Amit M Oza, Domenica Lorusso, et al.
Gynecologic Oncology
|
August 31, 2020
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma
Nicoletta Colombo, Amit M Oza, Domenica Lorusso, et al.
Geohealth
|
April 3, 2026
Developing Scenario-Based Strategies for Health, Climate, and Environmental Preparedness: The One Health, One Earth Approach
Azar M Abadi, Kyle D Brumfield, Moiz Usmani, et al.
Page
of 47